Physician profile
Faisal Tai
NPI 1619381316
$36,400.89
in general payments reported to CMS, 2019-2025
26 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $552 · 2021: $659 · 2022: $1,694 · 2023: $8,753 · 2024: $24K · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $3,705 · Travel and Lodging: $3,484 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,034.48 |
| Food and Beverage | $3,704.59 |
| Travel and Lodging | $3,483.68 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $31,013.84 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $1,848.76 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $826.91 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $516.46 | 2019-2024 | Austedo Xr |
| Abbvie INC. | $427.55 | 2021-2025 | Vraylar |
| Indivior INC. | $327.02 | 2021-2024 | Perseris, Sublocade |
| Allergan, INC. | $165.75 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $155.13 | 2021-2022 | |
| Lundbeck LLC | $147.02 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $133.37 | 2021-2024 | Trintellix |
| Janssen Scientific Affairs, LLC | $129.08 | 2025 | Spravato |
| Neurocrine Biosciences, INC. | $119.27 | 2020-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $101.47 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $81.91 | 2021-2022 | |
| Corium, LLC | $80.10 | 2022-2025 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $74.04 | 2023-2024 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $60.86 | 2022-2024 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $28.82 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.39 | 2022 | |
| Luye Pharma (USA) LTD. | $24.33 | 2025 | Erzofri Extended-Release |
| Jazz Pharmaceuticals INC. | $22.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.48 | 2025 | Cobenfy |
| Janssen Biotech, INC. | $18.89 | 2023 | |
| Ironshore Pharmaceuticals INC. | $18.42 | 2020 | |
| Adlon Therapeutics L.P. | $18.30 | 2021 | |
| Almatica Pharma LLC | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Tai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.